All our results highlight a tight association between KLF17 and TGF-β/Smad tumor suppressive functions and are endorsed by other publications that reduced KLF17 is potentially associated with advanced cancer progression.6, 7, 8, 9 Thus, cancer patients with higher levels of KLF17 may benefit from treatment with chemotherapeutic agents. The gene discussed is TGFB1; the disease is neoplasm.